Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Jilin, Changchun, China.
Department of Gastroenterology, The First Hospital of Jilin University, Jilin, Changchun, China.
Front Cell Infect Microbiol. 2024 Feb 9;14:1288222. doi: 10.3389/fcimb.2024.1288222. eCollection 2024.
Graves' disease (GD) is the most common cause of hyperthyroidism, and its pathogenesis remains incompletely elucidated. Numerous studies have implicated the gut microbiota in the development of thyroid disorders. This study employs Mendelian randomization analysis to investigate the characteristics of gut microbiota in GD patients, aiming to offer novel insights into the etiology and treatment of Graves' disease.
Two-sample Mendelian randomization (MR) analysis was employed to assess the causal relationship between Graves' disease and the gut microbiota composition. Gut microbiota data were sourced from the international consortium MiBioGen, while Graves' disease data were obtained from FINNGEN. Eligible single nucleotide polymorphisms (SNPs) were selected as instrumental variables. Multiple analysis methods, including inverse variance-weighted (IVW), MR-Egger regression, weighted median, weighted mode, and MR-RAPS, were utilized. Sensitivity analyses were conducted employing MR-Egger intercept test, Cochran's Q test, and leave-one-out analysis as quality control measures.
The Mendelian randomization study conducted in a European population revealed a decreased risk of Graves' disease associated with (Odds ratio (OR) [95% confidence interval (CI)]: 0.89 [0.89 ~ 0.90], adjusted value: <0.001), (OR: [95% CI]: 0.555 [0.437 ~ 0.706], adjusted value: <0.001), and (OR [95% CI]: 0.632 [0.492 ~ 0.811], adjusted value: 0.016). No significant evidence of heterogeneity, or horizontal pleiotropy was detected. Furthermore, the preliminary MR analysis identified 13 bacterial species including group and group, exhibiting significant associations with Graves' disease onset, suggesting potential causal effects.
A causal relationship exists between gut microbiota and Graves' disease. , , and emerge as protective factors against Graves' disease development. Prospective probiotic supplementation may offer a novel avenue for adjunctive treatment in the management of Graves' disease in the future.
格雷夫斯病（GD）是最常见的甲状腺功能亢进症病因，但其发病机制尚未完全阐明。许多研究表明肠道微生物群与甲状腺疾病的发生有关。本研究采用孟德尔随机分析研究 GD 患者肠道微生物群的特征，旨在为格雷夫斯病的病因和治疗提供新的见解。
采用两样本孟德尔随机分析（MR）评估格雷夫斯病与肠道微生物群组成之间的因果关系。肠道微生物群数据来自国际 MiBioGen 联盟，格雷夫斯病数据来自 FINNGEN。选择合适的单核苷酸多态性（SNP）作为工具变量。采用多种分析方法，包括逆方差加权（IVW）、MR-Egger 回归、加权中位数、加权众数和 MR-RAPS。采用 MR-Egger 截距检验、Cochran's Q 检验和逐一剔除分析作为质量控制措施进行敏感性分析。
在欧洲人群中进行的孟德尔随机研究表明，与格雷夫斯病相关的风险降低，（优势比（OR）[95%置信区间（CI）]：0.89 [0.89 ～ 0.90]，调整 值：<0.001），（OR：[95% CI]：0.555 [0.437 ～ 0.706]，调整 值：<0.001），和 （OR [95% CI]：0.632 [0.492 ～ 0.811]，调整 值：0.016）。未发现异质性或水平性多效性的显著证据。此外，初步的 MR 分析确定了 13 种细菌物种，包括 组和 组，与格雷夫斯病发病显著相关，提示存在潜在的因果关系。
肠道微生物群与格雷夫斯病之间存在因果关系。 、 、和 是格雷夫斯病发展的保护因素。前瞻性益生菌补充可能为未来格雷夫斯病的辅助治疗提供新的途径。
